Disease Intelligence Center · Pandemic II
Insulin Resistance (Prediabetes Pattern)
Insulin resistance means the body needs more insulin to keep glucose normal. It often comes years before type 2 diabetes. It is estimated with HOMA-IR = (fasting insulin µIU/mL × fasting glucose mg/dL) ÷ 405. Values of about 2.5 or more, a triglyceride/HDL ratio of 3 or more, or HbA1c of 5.7–6.4% suggest it. HOMA-IR cutoffs vary by population and assay, so it guides risk but does not diagnose.
Domain weighting
Organizational emphasisiWeightings describe where this framework directs attention for this condition. They are not a measure of how much any factor caused an individual case.
Root-cause chain
Each link carries its own evidence grade- Visceral adiposity→Hepatic and muscle insulin resistanceBA
Free-fatty-acid flux and adipokines impair insulin signalling; weight loss reverses it (DPP).
Relationship: Established causal
- Physical inactivity→Reduced glucose uptake by muscleOA
Exercise increases GLUT4 translocation independent of insulin.
Relationship: Randomized evidence
- Short or poor sleep→Lower insulin sensitivityOB
Sleep restriction trials reduce insulin sensitivity within days.
Relationship: Randomized evidence
- Endocrine-active chemicals (BPA, phthalates)→Insulin resistanceTD
NHANES associations and animal data; causation in humans is not established.
Relationship: Exposure signal
iDetection of an exposure does not establish that it caused a disease. This platform separates exposure, association, plausible mechanism, clinical evidence and demonstrated causation.
Fifth Estate considerations
Microbial ecologyGut microbiome composition associates with insulin sensitivity; microbiome treatments remain investigational.
Go deeper
TOBIN Intelligence LibraryThe full evidence review for Insulin Resistance (Prediabetes Pattern): each mechanism by domain, what is established versus uncertain, related pandemics, relevant labs and how they move your scores.
Open the Insulin Resistance (Prediabetes Pattern) evidence reviewProtocol Fusion Engine
Six lanes · evidence grade and regulatory status on every entryConventional
DPP: metformin cut progression to diabetes by 31%; ADA recommends considering it in these groups.
Caution: B12 deficiency with long use; avoid with low kidney function (eGFR < 30).
Functional
DPP: 58% fewer progressions to diabetes; effect lasting at 15 years.
Caution: Adapt to heart and joint limits.
Integrative
Improves insulin sensitivity in meta-analyses.
Caution: Progress gradually.
Orthomolecular
D2d trial: no significant overall diabetes prevention; correct only true deficiency.
Caution: Monitor calcium with high doses.
Traditional
PREDIMED: lower diabetes incidence.
Caution: Watch energy intake from oils and nuts.
Energy / Physical
Energy medicine on Tayapulse →Listed for completeness only.
Caution: Must not be presented as a treatment.
iLanes are presented side by side so the difference in evidence strength is visible. Nothing here is a prescription, and interactions must be reviewed with your clinician and pharmacist.
iEnergy and physical modalities in this lane are explored further with Tayapulse. Evidence grade and regulatory status still apply: these are adjuncts used only where indicated, never cures or replacements for guideline care.
Diagnostics to consider
- · Fasting glucose and fasting insulin → HOMA-IR
- · HbA1c
- · Triglycerides and HDL → TG/HDL ratio
- · Waist circumference and waist-to-height ratio (≥ 0.5)
- · ALT (fatty liver often co-exists)
Monitoring
- · HbA1c and fasting glucose every 6–12 months
- · HOMA-IR or fasting insulin trend
- · Waist and weight trend
- · TOBIN score change over time
Prevention emphasis
- · 150+ minutes of activity weekly plus resistance training
- · 7% weight loss where overweight (DPP)
- · 7–9 hours of sleep
- · Limit refined carbohydrates and sugary drinks